Morever, we assessed the efficacy of SIRT6-targeted therapy with a inhibitor OSS had effects on the restoration of airway remodeling via inhibiting IL-17A-mediated mesenchymal reprogramming and airway inflammation in acute and chronic experimental asthma. Here, IL17A is linked to asthma.